This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/business/8163027.stm
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Flu treatment output 'to triple' | Flu treatment output 'to triple' |
| (10 minutes later) | |
| Drugs giant GlaxoSmithKline says it expects to triple capacity of its flu treatment Relenza to 190 million treatments per year. | Drugs giant GlaxoSmithKline says it expects to triple capacity of its flu treatment Relenza to 190 million treatments per year. |
| Glaxo also said it had received contracts for 195 million doses of the H1N1 vaccine for swine flu, adding that it was on track to meet the orders. | Glaxo also said it had received contracts for 195 million doses of the H1N1 vaccine for swine flu, adding that it was on track to meet the orders. |
| It said it was involved in continuing talks with more than 50 governments to supply pandemic products. | It said it was involved in continuing talks with more than 50 governments to supply pandemic products. |
| Glaxo said pre-tax profits in the three months to 30 June fell 6% to £2.1bn. | |
| Group turnover during the quarter was down 2% to £6.7bn. | |
| Increasing production | |
| Glaxo said its performance had been boosted by sales of Relenza, "reflecting continued orders from governments across the world for pandemic stock-piling". | |
| Sales of the treatment were £60m in the quarter, compared with £3m in the same period a year ago. | |
| Since the outbreak of swine flu, Glaxo said it had committed to increasing production levels of Relenza and effectively developing a new H1N1 vaccine. | |
| Shipments of the vaccine are expected in the second half of 2009 and early 2010. |